Vancomycin Area under the Concentration-Time Curve Estimation Using Bayesian Modeling versus First-Order Pharmacokinetic Equations: A Quasi-Experimental Study

Aim: To evaluate the efficiency of Bayesian modeling software and first-order pharmacokinetic (PK) equations to calculate vancomycin area under the concentration-time curve (AUC) estimations. Methods: Unblinded, crossover, quasi-experimental study at a tertiary care hospital for patients receiving i...

Full description

Bibliographic Details
Main Authors: Yazed Saleh Alsowaida, David W. Kubiak, Brandon Dionne, Mary P. Kovacevic, Jeffrey C. Pearson
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Antibiotics
Subjects:
Online Access:https://www.mdpi.com/2079-6382/11/9/1239
_version_ 1797491822058012672
author Yazed Saleh Alsowaida
David W. Kubiak
Brandon Dionne
Mary P. Kovacevic
Jeffrey C. Pearson
author_facet Yazed Saleh Alsowaida
David W. Kubiak
Brandon Dionne
Mary P. Kovacevic
Jeffrey C. Pearson
author_sort Yazed Saleh Alsowaida
collection DOAJ
description Aim: To evaluate the efficiency of Bayesian modeling software and first-order pharmacokinetic (PK) equations to calculate vancomycin area under the concentration-time curve (AUC) estimations. Methods: Unblinded, crossover, quasi-experimental study at a tertiary care hospital for patients receiving intravenous vancomycin. Vancomycin AUC monitoring was compared using Bayesian modeling software or first-order PK equations. The primary endpoint was the time taken to estimate the AUC and determine regimen adjustments. Secondary endpoints included the percentage of vancomycin concentrations usable for AUC calculations and acute kidney injury (AKI). Results: Of the 124 patients screened, 34 patients had usable vancomycin concentrations that led to 44 AUC estimations. Without electronic health record (EHR) integration, the time from assessment to intervention in the Bayesian modeling platform was a median of 9.3 min (quartiles Q<sub>1</sub>–Q<sub>3</sub> 7.8–12.4) compared to 6.8 min (Q<sub>1</sub>–Q<sub>3</sub> 4.8–8.0) in the PK equations group (<i>p</i> = 0.004). With simulated Bayesian software integration into the EHR, however, the median time was 3.8 min (Q<sub>1</sub>–Q<sub>3</sub> 2.3–6.9, <i>p</i> = 0.019). Vancomycin concentrations were usable in 88.2% in the Bayesian group compared to 48.3% in the PK equation group and there were no cases of AKI. Conclusion: Without EHR integration, Bayesian software was more time-consuming to assess vancomycin dosing than PK equations. With simulated integration, however, Bayesian software was more time efficient. In addition, vancomycin concentrations were more likely to be usable for calculations in the Bayesian group.
first_indexed 2024-03-10T00:54:48Z
format Article
id doaj.art-660a878715864616969449a1a644a07b
institution Directory Open Access Journal
issn 2079-6382
language English
last_indexed 2024-03-10T00:54:48Z
publishDate 2022-09-01
publisher MDPI AG
record_format Article
series Antibiotics
spelling doaj.art-660a878715864616969449a1a644a07b2023-11-23T14:45:27ZengMDPI AGAntibiotics2079-63822022-09-01119123910.3390/antibiotics11091239Vancomycin Area under the Concentration-Time Curve Estimation Using Bayesian Modeling versus First-Order Pharmacokinetic Equations: A Quasi-Experimental StudyYazed Saleh Alsowaida0David W. Kubiak1Brandon Dionne2Mary P. Kovacevic3Jeffrey C. Pearson4Department of Clinical Pharmacy, College of Pharmacy, Hail University, Hail 81442, Saudi ArabiaDepartment of Pharmacy Services, Brigham and Women’s Hospital, Boston, MA 02115, USADepartment of Pharmacy Services, Brigham and Women’s Hospital, Boston, MA 02115, USADepartment of Pharmacy Services, Brigham and Women’s Hospital, Boston, MA 02115, USADepartment of Pharmacy Services, Brigham and Women’s Hospital, Boston, MA 02115, USAAim: To evaluate the efficiency of Bayesian modeling software and first-order pharmacokinetic (PK) equations to calculate vancomycin area under the concentration-time curve (AUC) estimations. Methods: Unblinded, crossover, quasi-experimental study at a tertiary care hospital for patients receiving intravenous vancomycin. Vancomycin AUC monitoring was compared using Bayesian modeling software or first-order PK equations. The primary endpoint was the time taken to estimate the AUC and determine regimen adjustments. Secondary endpoints included the percentage of vancomycin concentrations usable for AUC calculations and acute kidney injury (AKI). Results: Of the 124 patients screened, 34 patients had usable vancomycin concentrations that led to 44 AUC estimations. Without electronic health record (EHR) integration, the time from assessment to intervention in the Bayesian modeling platform was a median of 9.3 min (quartiles Q<sub>1</sub>–Q<sub>3</sub> 7.8–12.4) compared to 6.8 min (Q<sub>1</sub>–Q<sub>3</sub> 4.8–8.0) in the PK equations group (<i>p</i> = 0.004). With simulated Bayesian software integration into the EHR, however, the median time was 3.8 min (Q<sub>1</sub>–Q<sub>3</sub> 2.3–6.9, <i>p</i> = 0.019). Vancomycin concentrations were usable in 88.2% in the Bayesian group compared to 48.3% in the PK equation group and there were no cases of AKI. Conclusion: Without EHR integration, Bayesian software was more time-consuming to assess vancomycin dosing than PK equations. With simulated integration, however, Bayesian software was more time efficient. In addition, vancomycin concentrations were more likely to be usable for calculations in the Bayesian group.https://www.mdpi.com/2079-6382/11/9/1239vancomycinAUCBayesiantherapeutic drug monitoring
spellingShingle Yazed Saleh Alsowaida
David W. Kubiak
Brandon Dionne
Mary P. Kovacevic
Jeffrey C. Pearson
Vancomycin Area under the Concentration-Time Curve Estimation Using Bayesian Modeling versus First-Order Pharmacokinetic Equations: A Quasi-Experimental Study
Antibiotics
vancomycin
AUC
Bayesian
therapeutic drug monitoring
title Vancomycin Area under the Concentration-Time Curve Estimation Using Bayesian Modeling versus First-Order Pharmacokinetic Equations: A Quasi-Experimental Study
title_full Vancomycin Area under the Concentration-Time Curve Estimation Using Bayesian Modeling versus First-Order Pharmacokinetic Equations: A Quasi-Experimental Study
title_fullStr Vancomycin Area under the Concentration-Time Curve Estimation Using Bayesian Modeling versus First-Order Pharmacokinetic Equations: A Quasi-Experimental Study
title_full_unstemmed Vancomycin Area under the Concentration-Time Curve Estimation Using Bayesian Modeling versus First-Order Pharmacokinetic Equations: A Quasi-Experimental Study
title_short Vancomycin Area under the Concentration-Time Curve Estimation Using Bayesian Modeling versus First-Order Pharmacokinetic Equations: A Quasi-Experimental Study
title_sort vancomycin area under the concentration time curve estimation using bayesian modeling versus first order pharmacokinetic equations a quasi experimental study
topic vancomycin
AUC
Bayesian
therapeutic drug monitoring
url https://www.mdpi.com/2079-6382/11/9/1239
work_keys_str_mv AT yazedsalehalsowaida vancomycinareaundertheconcentrationtimecurveestimationusingbayesianmodelingversusfirstorderpharmacokineticequationsaquasiexperimentalstudy
AT davidwkubiak vancomycinareaundertheconcentrationtimecurveestimationusingbayesianmodelingversusfirstorderpharmacokineticequationsaquasiexperimentalstudy
AT brandondionne vancomycinareaundertheconcentrationtimecurveestimationusingbayesianmodelingversusfirstorderpharmacokineticequationsaquasiexperimentalstudy
AT marypkovacevic vancomycinareaundertheconcentrationtimecurveestimationusingbayesianmodelingversusfirstorderpharmacokineticequationsaquasiexperimentalstudy
AT jeffreycpearson vancomycinareaundertheconcentrationtimecurveestimationusingbayesianmodelingversusfirstorderpharmacokineticequationsaquasiexperimentalstudy